综述文章:在中晚期肝癌中实现精准肿瘤学
中晚期肝细胞癌(HCC)患者临床结局异质性显著,经动脉化疗栓塞(TACE)是标准治疗。本文综述多种预后模型(HAP、ART、ABCR评分等),这些模型有助于识别预后不良、可能更适合替代治疗或最佳支持治疗而非TACE的患者。当前证据提示新型预后算法可能带来获益,但在TACE实施中面临不可忽视的挑战。
要点
- 中晚期HCC患者临床结局异质性大,与肿瘤负荷、肝脏储备、种族及治疗方式差异有关。
- HAP、ART、ABCR评分等预后算法有助于早期识别预后不良患者,可能更适合替代治疗或最佳支持治疗。
- 新型预后算法在TACE实施中可能带来获益,但面临不可忽视的挑战。
核心结论
- 当前证据提示,中晚期HCC的新型预后算法可能带来潜在获益,但在TACE实施中面临不可忽视的挑战。
研究设计与样本
- 本文为综述文章,全面综述了已提出的用于优化接受TACE的HCC患者预后预测的多种预后模型。
主要发现
- 中晚期HCC患者临床结局异质性显著,变异来源包括肿瘤负荷、肝脏储备、种族和治疗方式的差异。
- HAP、ART、ABCR评分及许多其他预后算法已显示出解决中晚期HCC患者临床异质性的潜力。
- 这些算法有助于早期识别具有不良预后特征的患者,对这类患者替代治疗或最佳支持治疗可能比TACE更合适。
关键数值与推荐
- HAP、ART、ABCR评分等多种预后算法已显示出解决中晚期HCC临床异质性的潜力。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intermediate-stage hepatocellular carcinoma (HCC), for which trans-arterial chemoembolization (TACE) constitutes the standard of care, is a patient subgroup with significant heterogeneity in clinical outcome. Sources of variation relate to differences in tumour burden, hepatic reserve, ethnicity and treatment modalities. Increasing research efforts have been dedicated to minimise the clinical diversity of this patient population and enhance optimal provision of treatment. AIM: To comprehensively review the diverse prognostic models that have been proposed to refine the prognostic prediction of patients with HCC undergoing TACE. RESULTS: A number of prognostic algorithms (HAP, ART, ABCR score and many others) have shown potential to address the clinical heterogeneity characterising patients with intermediate-stage HCC and facilitate early identification of patients with poor prognostic features in whom alternative treatments or best supportive care might be more appropriate than TACE. CONCLUSIONS: While an improved characterisation of intermediate-stage HCC is a highly important clinical aim, current evidence suggests that novel prognostic algorithms in this patient population may offer potential benefits but non-negligible challenges in the provision of TACE. This review summarises the currently available evidence to facilitate the development of precision oncology in intermediate-stage HCC.
引用
- Pinato DJ, Howell J, Ramaswami R, et al. Review article: delivering precision oncology in intermediate-stage liver cancer. Aliment Pharmacol Ther. 2017. PMID: 28440552. doi:10.1111/apt.14066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。